|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 221.38 USD | +0.03% |
|
-.--% | +0.22% |
| 01-09 | Cidara Therapeutics, Inc.(NasdaqCM:CDTX) dropped from Russell 2000 Value Benchmark | CI |
| 01-09 | Cidara Therapeutics, Inc.(NasdaqCM:CDTX) dropped from Russell 2500 Value Benchmark | CI |
| Market Cap | 6.96B 6B 5.52B 5.2B 9.76B 657B 9.84B 65.41B 25.47B 322B 26.12B 25.56B 1,115B | P/E 2023 |
-3.03x | P/E 2024 | -1.01x |
|---|---|---|---|---|---|
| Enterprise Value | 6.77B 5.84B 5.37B 5.06B 9.5B 639B 9.58B 63.66B 24.78B 314B 25.42B 24.88B 1,085B | EV / Sales 2023 |
0.64x | EV / Sales 2024 | 84.5x |
| Free-Float |
-
| Yield 2023 * |
-
| Yield 2024 | - |
Last Transcript: Cidara Therapeutics
| 1 day | +0.03% | ||
| 6 months | +0.60% | ||
| Current year | +0.22% |
| Current year | 220.47 |  | 221.42 |
| 1 year | 20.16 | | 221.42 |
| 3 years | 10 | | 221.42 |
| 5 years | 8 | | 221.42 |
| 10 years | 8 | | 259 |
| Manager | Title | Age | Since |
|---|---|---|---|
Frank Karbe
DFI | Director of Finance/CFO | 58 | 24/02/2025 |
Corrina Pavetto
CTO | Chief Tech/Sci/R&D Officer | - | 01/05/2025 |
| Chief Tech/Sci/R&D Officer | - | 01/05/2025 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 01-07 | Issuer sale | Director | 41,100 | 0.1621% | ||
| 01-07 | Issuer sale | Director | 42,920 | 0.1693% | ||
| 01-07 | Issuer sale | Director | 35,390 | 0.1396% |
| 2023 | 2024 | |
|---|---|---|
| Net sales | 63.9M 55.13M 50.69M 47.71M 89.65M 6.03B 90.4M 601M 234M 2.96B 240M 235M 10.24B | 1.28M 1.1M 1.01M 952K 1.79M 120M 1.8M 11.98M 4.67M 59.05M 4.79M 4.68M 204M |
| Net income | -22.93M -19.78M -18.19M -17.12M -32.17M -2.16B -32.44M -216M -83.91M -1.06B -86.06M -84.23M -3.67B | -170M -147M -135M -127M -238M -16.03B -240M -1.6B -621M -7.87B -637M -624M -27.21B |
| Net Debt | -30.9M -26.66M -24.51M -23.07M -43.35M -2.92B -43.71M -290M -113M -1.43B -116M -113M -4.95B | -186M -161M -148M -139M -261M -17.58B -263M -1.75B -682M -8.63B -699M -684M -29.84B |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
- Stock Market
- Stocks
- CDTX Stock
Select your edition
All financial news and data tailored to specific country editions
